The companies collaborated to identify biomarkers of response to Onconova’s rigosertib using Pangea Biomed’s algorithmic platform ENLIGHT. Under the research collaboration, Onconova holds all rights to rigosertib & will own intellectual property
The collaboration was based on the clinical data which showed an anti-cancer activity of rigosertib with checkpoint inhibition for KRAS-mutated NSCLC & rigosertib monotx. for advanced SCC. Onconova also informs a precision medicine approach toward rigosertib’s evaluation in new indications
Rigosertib is being studied in multiple investigator-sponsored studies, incl. a dose-escalation & expansion P-I/IIa study in combination with nivolumab for KRAS+ NSCLC & in P-II program for advanced RDEB-associated SCC
Ref: Globenewswire | Image: Onconova Therapeutics
Related News:- Specialised Therapeutics Signs an Exclusive License Agreement with Onconova Therapeutics for Rigosertib
